ESMO-IO 2019 – Personalised ovarian cancer vaccines show promise


  • Carolina Rojido
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Personalised vaccines from neoantigens using dendritic cells as targets for activation could radically improve overall survival.1

Why this matters

  • Most patients with ovarian cancer (85%) relapse after first-line treatment.
  • Intratumoral T cells have been found to be present in 55% of ovarian tumours.

Key results

  • Very few grade 3-4 adverse events.
  • Clinical response correlated with immune response (IFN).
  • T-cell responses induced by the vaccine were polyfunctional.
  • Conclusions on personalised whole tumour antigen vaccines:
    • Induce responses that correlate with progression-free survival.
    • 2-year overall survival (OS) rates of the responder patients were 100%, whereas the 2-year OS of non-responders were 25%.2
    • Must be combined with standard of care immunomodulatory treatment (bevacizumab and cyclophosphamide) for added synergistic effect.
    • Enhanced pre-existing response against some neo-epitopes and induced newly detected responses against additional neo-epitopes.
    • Have potential in patients with low mutational load for which a sufficient amount of tumour is available to produce the vaccine.

Study design

  • Phase 1 clinical trial of autologous dendritic cell vaccine loaded with autologous tumour cell lysate for recurring ovarian cancer.
  • The immunogenicity of tumour cells was optimised by exposing them to hypochlorous acid.
  • Administration was by intra-nodal injection.
  • Average 16 doses per patient and 174 intranodal injections.

Limitations

  • Very small, early stage study.